Final results of the prospective FH02 mammographic surveillance study of women aged 35-39 at increased familial risk of breast cancer
Authors
Evans, D Gareth RThomas, S
Caunt, J
Burch, A
Brentnall, A
Roberts, L
Howell, Anthony
Wilson, M
Fox, R
Hillier, S
Sibbering, D
Moss, S
Wallis, M
Eccles, D
Duffy, S
Affiliation
Prevent Breast Cancer Centre, Wythenshawe Hospital Manchester Universities Foundation Trust, Wythenshawe, Manchester M23 9LT, UKIssue Date
2019
Metadata
Show full item recordAbstract
Background: Many women who are at increased risk of breast cancer due to a mother or sister diagnosed with breast cancer aged under 40 do not currently qualify for surveillance before 40?years of age. There are almost no available data to assess whether mammography screening aged 35-39?years would be effective in this group, in terms of detection of breast cancer at an early stage or cost effective. Methods: A cohort screening study (FH02) with annual mammography was devised for women aged 35-39 to assess the sensitivity and screening performance and potential survival of women with identified tumours. Findings: 2899 women were recruited from 12/2006-12/2015. These women underwent 12,086 annual screening mammograms and were followed for 13,365.8?years. A total of 55 breast cancers in 54 women occurred during the study period (one bilateral) with 50 cancers (49 women) (15 CIS) adherent to the screening. Eighty percent (28/35) of invasive cancers were ? 2?cm and 80% also lymph node negative. Invasive cancers diagnosed in FH02 were significantly smaller than the comparable (POSH-unscreened prospective) study group (45% (131/293)???2?cm in POSH vs 80% (28/35) in FH02 p?<?0.0001), and were less likely to be lymph-node positive (54% (158/290, 3 unknown) in POSH vs 20% (7/35) in FH02: p?=?0.0002. Projected and actual survival were also better than POSH. Overall radiation dose was not higher than in an older screened population at mean dose on study per standard sized breast of 1.5?mGy. Interpretation: Mammography screening aged 35-39?years detects breast cancer at an early stage and is likely to be as effective in reducing mortality as in women at increased breast cancer risk aged 40-49?years.Citation
Evans DG, Thomas S, Caunt J, Burch A, Brentnall AR, Roberts L, et al. Final results of the prospective FH02 mammographic surveillance study of women aged 35-39 at increased familial risk of breast cancer. EClinicalMedicine. 2019; 7:39-46.Journal
EClinicalMedicineDOI
10.1016/j.eclinm.2019.01.005PubMed ID
31008449Additional Links
https://dx.doi.org/10.1016/j.eclinm.2019.01.005Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.eclinm.2019.01.005
Scopus Count
Collections
Related articles
- Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02).
- Authors: Evans DG, Thomas S, Caunt J, Roberts L, Howell A, Wilson M, Fox R, Sibbering DM, Moss S, Wallis MG, Eccles DM, FH02 study group, Duffy S
- Issue date: 2014 Mar
- Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
- Authors: Medical Advisory Secretariat
- Issue date: 2007
- Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.
- Authors: FH01 collaborative teams
- Issue date: 2010 Dec
- MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
- Authors: Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA, FaMRIsc study group
- Issue date: 2019 Aug
- Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
- Authors: Piver MS
- Issue date: 1996